Phototherapy Guidelines for Neonatal Jaundice

Decision Framework Based on Risk Factors

The American Academy of Pediatrics recommends phototherapy for a 4-day-old infant with a total bilirubin of 14.8 mg/dL if the infant has any risk factors for neurotoxicity or is less than 38 weeks gestational age 1, 2
Gestational age < 38 weeks is a high-risk factor for bilirubin-related neurotoxicity, requiring a lower threshold for phototherapy 3, 4
Evidence of hemolysis, indicated by positive direct antibody test, elevated reticulocyte count, or abnormal blood smear, is a high-risk factor for neurotoxicity 3, 4
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a high-risk factor for neurotoxicity, suggested by ethnic or geographic origin or poor response to phototherapy 3, 4
Serum albumin < 3.0 g/dL reduces bilirubin binding capacity and increases risk of neurotoxicity 3, 1
Significant weight loss (>12% from birth weight) or clinical/biochemical evidence of dehydration is a high-risk factor for neurotoxicity 4, 2

For a 4-day-old infant with TSB of 14.8 mg/dL, phototherapy should be initiated immediately if high-risk factors are present 1, 2
Intensive phototherapy with blue-green spectrum light (430-490 nm wavelength) should be used 5, 2
Irradiance of at least 30 mW/cm² per nm measured at the infant's skin is recommended 5, 2
Maximize skin exposure (remove diaper when bilirubin levels approach exchange transfusion range) 5, 2
Continue breastfeeding or bottle-feeding every 2-3 hours during phototherapy 6, 2

For TSB < 20 mg/dL, repeat TSB measurement in 4-6 hours after initiating phototherapy 4, 2
Monitor for signs of acute bilirubin encephalopathy (hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry) 3, 5
Assess hydration status and supplement with expressed breast milk or formula if needed 6, 2

Discontinue phototherapy when TSB falls below 13-14 mg/dL 6, 2
Follow-up TSB measurement within 24 hours after discontinuation for infants with hemolytic disease or those who received phototherapy before 3-4 days of age 1, 2

For infants with cholestatic jaundice receiving phototherapy, monitor for bronze infant syndrome (dark, grayish-brown discoloration of skin, serum, and urine) 6, 5
Intravenous immunoglobulin (0.5-1 g/kg) should be considered for infants with isoimmune hemolytic disease with rapidly rising TSB levels 3, 4
Exchange transfusion should be considered if TSB continues to rise despite intensive phototherapy or if signs of acute bilirubin encephalopathy develop 3, 5